Which medications in the drug class Antineoplastics, Tyrosine Kinase Inhibitor are used in the treatment of Pediatric Acute Lymphoblastic Leukemia?

Updated: Jan 03, 2019
  • Author: Vikramjit S Kanwar, MBBS, MBA, MRCP(UK), FAAP; Chief Editor: Jennifer Reikes Willert, MD  more...
  • Print
Answer

Antineoplastics, Tyrosine Kinase Inhibitor

When added to chemotherapy, tyrosine kinase inhibitors (TKIs) have been shown to improve progression-free survival in newly diagnosed patients with Ph+ ALL. [58, 59]

Imatinib (Gleevec)

Imatinib is a selective BCR-ABL tyrosine kinase inhibitor. It is indicated for newly diagnosed children aged 1 y or older with Ph+ ALL in combination with chemotherapy.

Dasatinib (Sprycel)

Second generation TKI indicated for newly diagnosed children aged 1 y or older with Philadelphia chromosome positive (Ph+) ALL in combination with chemotherapy. Compared with imatinib, dasatinib has increased potency, CNS penetration, and activity against imatinib-resistant clones.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!